David Veenstra


CHOICE Faculty, Department of Pharmacy, Pharmacy Faculty, School Faculty

Telephone: 206.221.6936

Email: veenstra@uw.edu

Office Location: H375-P


  • PharmD, University of California, San Francisco
  • PhD in Pharmaceutical Chemistry, University of California, San Francisco

Research Interests

  • Precision medicine
  • Cost-effectiveness analysis
  • Managed care decision making

Courses Taught

  • Pharm 520: Introduction to Pharmacoeconomics
  • Pharm 542: Managed Care Pharmacy


Dr. Veenstra is a Professor in the Comparative Health Outcomes, Policy & Economics (CHOICE) Institute in the Department of Pharmacy at the University of Washington.

Dr. Veenstra’s primary research interests are the clinical, economic, and policy implications of precision medicine. His major research projects include evaluation of the cost effectiveness of population-level genomic screening, and evidence thresholds and preferences for precision medicine.

Dr. Veenstra’s research has been funded through grants from the National Human Genome Research Institute, Centers for Disease Control, and the National Cancer Institute.
He also has worked extensively with organizations such as the Academy of Managed Care Pharmacy (AMCP) and the Institute for Clinical and Economic Review (ICER) to further the practical application of cost-effectiveness analysis in managed care decision making.

Dr. Veenstra teaches courses in health economics and managed care and is an author of five book chapters and 240 peer-reviewed publications.

Recent Publications

  1. Guzauskas GF, Garbett S, Zhou Z, Schildcrout JS, Graves JA, Williams MS, Hao J, Jones LK, Spencer SJ, Jiang S, Veenstra DL*, Peterson JF*. Population Genomic Screening for Three Common Hereditary Conditions: A Cost-Effectiveness Analysis. Ann Intern Med. 2023 May;176(5):585-595. PMID: 37155986
  2. Lee W, Dayer V, Jiao B, Carlson JJ, Devine B, Veenstra DL. Use of real-world evidence in economic assessments of pharmaceuticals in the United States. J Manag Care Spec Pharm. 2021 Jan;27(1):5-14. PMID: 33377439
  3. Guzauskas GF, Basu A, Veenstra DL. Are there different evidence thresholds for genomic vs. clinical precision medicine? A VOI-based framework applied to antiplatelet drug therapy. Value in Health, 2019.
  4. Dhanda DS, Veenstra DL, Regier DA, Basu A, Carlson JJ. Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment. J Manag Care Spec Pharm. 2020 Apr;26(4):529-537. PMID: 32223606
  5. Henderson LM, Robinson RF, Ray L, Li T, Dillard DA, Schilling BD, Mosley M, Janssen PL, Fohner AE, Rettie AE, Thummel KE, Thornton TA, Veenstra DL. VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People. Clin Transl Sci. 2019 Mar 1. PMID: 30821933.